Hookipa Pharma Inc (NASDAQ:HOOK) Position Trimmed by GSA Capital Partners LLP

GSA Capital Partners LLP trimmed its stake in Hookipa Pharma Inc (NASDAQ:HOOK) by 86.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,609 shares of the company’s stock after selling 103,028 shares during the quarter. GSA Capital Partners LLP owned 0.14% of Hookipa Pharma worth $71,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Virtu Financial LLC acquired a new position in Hookipa Pharma in the 1st quarter valued at approximately $31,000. Renaissance Technologies LLC boosted its stake in shares of Hookipa Pharma by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after buying an additional 83,800 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in shares of Hookipa Pharma by 12.3% during the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after acquiring an additional 108,844 shares in the last quarter. 63.88% of the stock is owned by hedge funds and other institutional investors.

Hookipa Pharma Stock Up 6.3 %

Shares of HOOK opened at $2.29 on Tuesday. The firm has a market cap of $27.56 million, a price-to-earnings ratio of -0.61 and a beta of 0.84. The company’s fifty day moving average is $3.79 and its 200-day moving average is $5.44. Hookipa Pharma Inc has a 12 month low of $2.08 and a 12 month high of $11.30.

Analysts Set New Price Targets

Several brokerages recently issued reports on HOOK. JMP Securities cut their price objective on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a report on Thursday, November 21st. Royal Bank of Canada cut their price target on Hookipa Pharma from $50.00 to $48.00 and set an “outperform” rating for the company in a research note on Friday, November 15th.

Hookipa Pharma Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.